FDA: Frequent Tysabri use raises risk of brain infection

02/6/2010 | Sun (Baltimore), The

The FDA warned doctors that the risk of a rare brain inflammation, progressive multifocal leukoencephalopathy, increases the longer patients use Tysabri, a multiple sclerosis drug from Biogen Idec and Elan. The warning comes after the agency confirmed 31 cases of PML, including eight deaths.

View Full Article in:

Sun (Baltimore), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC